Vispacabtagene Regedleucel

N/A

Report date: 2025/11/07 18:00:02

Base Information

Drug NameVispacabtagene Regedleucel
Drug Alias Namevispa-celCB-010
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousLupus Nephritis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaIsrael
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCaribou Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCaribou Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLymphoma
Inactive IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousLupus Nephritis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A